Gilead Sciences (GILD) Competitors

$133.73 -0.63 (-0.47%)

As of 04:00 PM Eastern

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

Should you buy Gilead Sciences stock or one of its competitors? MarketBeat compares Gilead Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gilead Sciences include Amgen (AMGN), Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Gilead Sciences compare to Amgen?

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Gilead Sciences had 29 more articles in the media than Amgen. MarketBeat recorded 66 mentions for Gilead Sciences and 37 mentions for Amgen. Amgen's average media sentiment score of 1.17 beat Gilead Sciences' score of 0.98 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	32 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	38 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has lower revenue, but higher earnings than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.93	$7.71B	$14.37	23.38
Gilead Sciences	$29.44B	5.64	$8.51B	$7.34	18.22

Amgen has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Amgen pays out 70.1% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Gilead Sciences	30.99%	48.19%	18.28%

Amgen currently has a consensus target price of $355.19, suggesting a potential upside of 5.73%. Gilead Sciences has a consensus target price of $156.93, suggesting a potential upside of 17.35%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Amgen and Gilead Sciences tied by winning 10 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Gilead Sciences (NASDAQ:GILD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Gilead Sciences presently has a consensus target price of $156.93, suggesting a potential upside of 17.35%. Ligand Pharmaceuticals has a consensus target price of $257.71, suggesting a potential upside of 9.51%. Given Gilead Sciences' higher probable upside, equities analysts plainly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Gilead Sciences had 60 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 66 mentions for Gilead Sciences and 6 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat Gilead Sciences' score of 0.98 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	38 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.64	$8.51B	$7.34	18.22
Ligand Pharmaceuticals	$268.09M	17.59	$124.45M	$7.37	31.93

Ligand Pharmaceuticals has a net margin of 55.95% compared to Gilead Sciences' net margin of 30.99%. Gilead Sciences' return on equity of 48.19% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Gilead Sciences on 9 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Moderna?

Gilead Sciences (NASDAQ:GILD) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Gilead Sciences has a net margin of 30.99% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 48.19% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Moderna	-143.55%	-26.64%	-19.32%

Gilead Sciences currently has a consensus price target of $156.93, suggesting a potential upside of 17.35%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 24.02%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

In the previous week, Gilead Sciences had 53 more articles in the media than Moderna. MarketBeat recorded 66 mentions for Gilead Sciences and 13 mentions for Moderna. Gilead Sciences' average media sentiment score of 0.98 beat Moderna's score of -0.11 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	38 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.64	$8.51B	$7.34	18.22
Moderna	$1.94B	9.60	-$2.82B	-$8.15	N/A

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Gilead Sciences beats Moderna on 13 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Gilead Sciences had 33 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 66 mentions for Gilead Sciences and 33 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.98 beat Regeneron Pharmaceuticals' score of 0.58 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Gilead Sciences	38 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Gilead Sciences	30.99%	48.19%	18.28%

Regeneron Pharmaceuticals currently has a consensus target price of $792.65, indicating a potential upside of 24.90%. Gilead Sciences has a consensus target price of $156.93, indicating a potential upside of 17.35%. Given Regeneron Pharmaceuticals' higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.68	$4.50B	$41.04	15.46
Gilead Sciences	$29.44B	5.64	$8.51B	$7.34	18.22

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 15 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Vir Biotechnology?

Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

In the previous week, Gilead Sciences had 65 more articles in the media than Vir Biotechnology. MarketBeat recorded 66 mentions for Gilead Sciences and 1 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 0.98 beat Vir Biotechnology's score of 0.00 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	38 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gilead Sciences presently has a consensus price target of $156.93, indicating a potential upside of 17.35%. Vir Biotechnology has a consensus price target of $20.25, indicating a potential upside of 115.88%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gilead Sciences has a net margin of 30.99% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of 48.19% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.64	$8.51B	$7.34	18.22
Vir Biotechnology	$68.56M	23.07	-$437.99M	-$3.13	N/A

Summary

Gilead Sciences beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GILD vs. The Competition

Export

Metric	Gilead Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$166.82B	$3.39B	$6.46B	$12.34B
Dividend Yield	2.44%	2.26%	2.75%	5.28%
P/E Ratio	18.22	18.67	21.07	25.81
Price / Sales	5.64	339.05	555.43	88.28
Price / Cash	12.83	125.17	43.49	56.67
Price / Book	7.09	7.10	10.36	7.17
Net Income	$8.51B	$24.25M	$3.56B	$336.99M
7 Day Performance	2.48%	6.83%	4.45%	4.51%
1 Month Performance	2.55%	2.46%	1.86%	3.09%
1 Year Performance	24.55%	64.06%	34.79%	37.67%

Gilead Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GILD Gilead Sciences	4.6619 of 5 stars	$133.73 -0.5%	$156.93 +17.3%	+25.1%	$166.82B	$29.44B	18.22	17,000	Analyst Revision
AMGN Amgen	3.9905 of 5 stars	$324.39 -0.6%	$356.15 +9.8%	+24.9%	$175.07B	$36.75B	22.57	31,500	Positive News Analyst Upgrade
LGND Ligand Pharmaceuticals	3.4186 of 5 stars	$207.89 -2.5%	$257.71 +24.0%	+125.7%	$4.17B	$268.09M	28.21	80
MRNA Moderna	1.2924 of 5 stars	$48.11 -1.9%	$35.73 -25.7%	+78.5%	$19.09B	$1.94B	N/A	4,700	Analyst Forecast
REGN Regeneron Pharmaceuticals	4.7842 of 5 stars	$629.68 -9.8%	$800.57 +27.1%	+8.6%	$66.57B	$14.34B	15.34	15,410	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GILD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Summary

How does Gilead Sciences compare to Moderna?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Do institutionals & insiders hold more shares of AMGN or GILD?

Does the media prefer AMGN or GILD?

Which has better earnings & valuation, AMGN or GILD?

Which has more risk & volatility, AMGN or GILD?

Is AMGN or GILD a better dividend stock?

Is AMGN or GILD more profitable?

Do analysts prefer AMGN or GILD?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Do analysts rate GILD or LGND?

Does the media favor GILD or LGND?

Do insiders and institutionals hold more shares of GILD or LGND?

Which has better earnings & valuation, GILD or LGND?

Is GILD or LGND more profitable?

Which has more risk and volatility, GILD or LGND?

Summary

How does Gilead Sciences compare to Moderna?

Is GILD or MRNA more profitable?

Do analysts rate GILD or MRNA?

Which has more volatility and risk, GILD or MRNA?

Does the media favor GILD or MRNA?

Which has higher valuation & earnings, GILD or MRNA?

Do institutionals & insiders hold more shares of GILD or MRNA?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Does the media refer more to REGN or GILD?

Is REGN or GILD more profitable?

Do analysts rate REGN or GILD?

Is REGN or GILD a better dividend stock?

Which has better earnings and valuation, REGN or GILD?

Do insiders and institutionals believe in REGN or GILD?

Which has more volatility & risk, REGN or GILD?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Which has more volatility & risk, GILD or VIR?

Does the media favor GILD or VIR?

Do analysts prefer GILD or VIR?

Do insiders & institutionals believe in GILD or VIR?

Is GILD or VIR more profitable?

Which has stronger earnings & valuation, GILD or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools